A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Through our ownership stake in and our license to Genevant Sciences, Ltd (Genevant), we are also focused on maximizing opportunity for our in-house developed Lipid Nanoparticle (LNP) delivery technology. We continue to protect and defend our intellectual property, which is the subject of our ongoing lawsuits against Moderna Therapeutics, Inc. (Moderna) and against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of our patented LNP delivery technology in their COVID-19 mRNA-LNP vaccines.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 15M | - | - | 39M | - | - |
| Net Income | -42M | -70M | -73M | -69M | -88M | -76M |
| EPS | $-0.23 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 |
| Free Cash Flow | -45M | -65M | -87M | -36M | -68M | -52M |
| ROIC | -37.8% | -68.8% | -68.7% | -50.8% | -52.2% | -74.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -47M | -76M | -78M | -65M | -74M | -58M |
| Operating Margin | -320.4% | - | - | -167.8% | - | - |
| ROE | -54.6% | -68.8% | -68.7% | -50.8% | -52.2% | -74.4% |
| Shares Outstanding | 192M | 184M | 166M | 151M | 106M | 76M |
Arbutus Biopharma Corp passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -22.4%.
Arbutus Biopharma Corp (ABUS) has a 5-year average return on invested capital (ROIC) of -63.0%. This is below average and may indicate limited pricing power.
Arbutus Biopharma Corp (ABUS) has a market capitalization of $837M. It is classified as a small-cap stock.
Arbutus Biopharma Corp (ABUS) does not currently pay a regular dividend.
Arbutus Biopharma Corp (ABUS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Arbutus Biopharma Corp (ABUS) generated $-65 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arbutus Biopharma Corp (ABUS) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Arbutus Biopharma Corp (ABUS) reported earnings per share (EPS) of $-0.38 in its most recent fiscal year.
Arbutus Biopharma Corp (ABUS) has a return on equity (ROE) of -68.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for Arbutus Biopharma Corp (ABUS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arbutus Biopharma Corp (ABUS) has a book value per share of $0.53, based on its most recent annual SEC filing.
No recent press releases.